Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design
Open Access
- 27 February 2025
- journal article
- review article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (3) , 505-518
Abstract
The emergence of personalized RNA therapeutics, tailored to individual patients' genetic profiles, offers new hope for treating both common and rare diseases. This review explores regulatory aspects of N-of-1 and N-of-few approaches, providing promising treatments for ultra- or nano-rare diseases that lack established therapies. These diseases present unique challenges, as patients may represent the sole individual or a small group worldwide with a specific mutation, necessitating personalized approaches to treatment development, validation, and approval. While progress is promising, the regulatory landscape remains nascent, raising challenges in ensuring safety and industry sustainability. Artificial intelligence (AI) and automated systems, coupled with real-world evidence (RWE) monitoring, offer significant potential to address these challenges by optimizing development, manufacturing, and regulatory compliance. Drawing parallels from other regulatory domains, this review presents a design envelope framework, integrated with AI tools, to streamline the approval process and enhance the adaptability of RNA-based treatments. Case studies of individualized RNA-based treatments highlight successes and setbacks, underscoring the need for regulatory alignment. Collaborative efforts from stakeholders and regulatory authorities are essential to refine this framework for real-world application. Overall, this review emphasizes the transformative potential of personalized RNA therapeutics in advancing precision medicine.Keywords
This publication has 26 references indexed in Scilit:
- Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense OligonucleotidesNucleic Acid Therapeutics, 2022
- Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunitiesThe Lancet Neurology, 2022
- Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical PerspectivesNucleic Acid Therapeutics, 2022
- Addressing the Needs of Patients with Ultra-Rare Mutations One Patient at a Time: The n-Lorem ApproachNucleic Acid Therapeutics, 2022
- Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosisNature Medicine, 2022
- Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotideNature Medicine, 2021
- ‘N of 1’ therapies need a better modelNature Medicine, 2021
- Epidemiology of rare diseases is importantJournal of the European Academy of Dermatology and Venereology, 2021
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic DiseaseNew England Journal of Medicine, 2019
- Patient reported outcome measures in rare diseases: a narrative reviewOrphanet Journal of Rare Diseases, 2018